KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $43.6 million.

  • Pacira BioSciences' Cash from Investing Activities rose 18361.1% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.8 million, marking a year-over-year increase of 20703.84%. This contributed to the annual value of -$83.3 million for FY2024, which is 20739.61% down from last year.
  • Pacira BioSciences' Cash from Investing Activities amounted to $43.6 million in Q3 2025, which was up 18361.1% from $62.2 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Cash from Investing Activities registered a high of $66.9 million during Q4 2021, and its lowest value of -$208.0 million during Q1 2022.
  • In the last 5 years, Pacira BioSciences' Cash from Investing Activities had a median value of -$368000.0 in 2024 and averaged -$9.0 million.
  • As far as peak fluctuations go, Pacira BioSciences' Cash from Investing Activities soared by 53175.07% in 2022, and later plummeted by 110135.88% in 2024.
  • Pacira BioSciences' Cash from Investing Activities (Quarter) stood at $66.9 million in 2021, then tumbled by 83.28% to $11.2 million in 2022, then decreased by 25.16% to $8.4 million in 2023, then plummeted by 104.39% to -$368000.0 in 2024, then surged by 11951.63% to $43.6 million in 2025.
  • Its Cash from Investing Activities was $43.6 million in Q3 2025, compared to $62.2 million in Q2 2025 and -$25.6 million in Q1 2025.